PharmaNutrients launches CLA One DG
The new, patented, dual mechanism technology delivers CLA One as a diglyceride, suitable for use in dietary supplements and food products.
10/03/05 PharmaNutrients, a leading research and development company and supplier of proprietary, science-based nutritional ingredients, has launched its latest in a series of innovations, CLA One DG. This new, patented, dual mechanism technology delivers CLA One as a diglyceride, suitable for use in dietary supplements and food products.
CLA One DG combines the well-recognized benefits of CLA One for reducing fat mass and increasing lean muscle mass with the attributes of diglyceride oil, shown to lower triglycerides (TG), reduce fat stores and increase fat burning. Until now CLA One has only been available as a free fatty acid (FFA); as a DG, CLA One enhances healthy fat loss due to the positioning of the fatty acids. This small change impacts fat absorption and metabolism causing less TG's to be formed in gut cells, releasing fewer plasma TG's into circulation and reducing the amount of fat deposited.
Dedicated to creating products to enhance wellness, PharmaNutrients supports research investigating fatty acids and soluble fibers. The company's activities encompass multiple technology platforms focused on creating solutions for obesity-related health issues including weight management, inflammation, diabetes and cardiovascular health. PharmaNutrients' conjugated linoleic acid and chitosan-based products are used in a wide range of dietary supplements.
PharmaNutrients is recognized for creating Tonalin CLA, the first nutritional dietary supplement targeted at "Body Composition" and creating the "Fat Binding" category with Absorbitol brand chitosan complex. Since its de-merger with Natural ASA of Norway in 1999, PharmaNutrients has further developed new applications for CLA beyond weight management and has filed numerous patents.
